Cardiogen (AEDR): Evidence, Mechanism, Dosing & Legal Status

Cardiogen is the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR), one of a family of ultrashort 'peptide bioregulators' developed by Vladimir Khavinson's group at the Russian Military Medical Academy and the St. Petersburg Institute of Bioregulation and Gerontology. It is the cardiac counterpart to the family's other organ-specific peptides — for example AEDG (Epitalon, pineal), KE (Vilon) and EDR (Pinealon).53 Its popularity in longevity and 'heart support' circles is real; its proof in humans is not. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Cardiogen is not an FDA-approved drug; it is sold as a 'research chemical not for human use' and has no human clinical data. Dosing figures are reported strictly as seen in the gray-market literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Cardiogen and how does it work?

Cardiogen is the synthetic tetrapeptide H-Ala-Glu-Asp-Arg-OH (AEDR), with a reported molecular formula of C18H31N7O9 and a molecular weight near 489.5 Da.5 It was designed to mimic short peptide fractions isolated from cardiac-tissue extracts, part of the Khavinson school's broader program of 2-to-4-residue 'bioregulators' synthesized from the 1980s and 1990s onward.5

The defining mechanistic hypothesis — all of it preclinical — is direct epigenetic regulation. Khavinson's group proposes that peptides this short can penetrate both the cell membrane and the nuclear envelope, enter nuclei and nucleoli, and bind directly to histone proteins and to single- and double-stranded DNA, modulating chromatin accessibility and therefore transcription without altering the DNA sequence.3 In that review, AEDR is specifically reported to bind histones H1, H2b, H3 and H4, and the AED-core peptides are reported to modulate methylation-state-dependent DNA hydrolysis by eukaryotic endonucleases.3 The nuclear-penetration claim has some independent-method support: fluorescence-labeled short peptides (including EDR, the C-terminal tripeptide of AEDR) were shown to enter HeLa-cell nuclei and bind DNA sequence-specifically in vitro.4 The chemically plausible DNA-contact residue is the C-terminal arginine, whose guanidinium group can form salt bridges with DNA phosphate — a canonical histone-DNA motif, though not Cardiogen-specific.

Downstream, in mouse embryonic fibroblasts a 30-minute incubation with AEDR raised cytoskeletal proteins (actin, tubulin, vimentin) two- to fivefold and nuclear-matrix lamins A and C two- to threefold, interpreted as the molecular basis of a pro-proliferative, anti-apoptotic action.2 Critically, no pharmacokinetic data exist for Cardiogen in humans or animals — no measured plasma half-life, bioavailability, distribution or clearance has been published. As a small, charged, peptide-bond-containing molecule it would be expected to face rapid peptidase degradation and negligible oral bioavailability, but that is inference, not data.

What is the evidence by indication?

Every indication below is supported by animal or in-vitro data only. No human randomized controlled trials, cohorts or case series exist, and a search of ClinicalTrials.gov, the WHO ICTRP, the EU Clinical Trials Register and PubMed returns no registered or completed human trial of AEDR for any purpose.1 The grades reflect that ceiling.

The single most-cited primary study used organotypic explant cultures of myocardial tissue from 3-month ('young') and 24-month ('old') rats, treating with AEDR at 10^-12 molar. Cardiogen produced a strong stimulating effect on proliferation in both young and aged tissue, whereas the constituent amino acids did not reproduce the effect at the same concentration — indicating the activity requires the intact tetrapeptide.1 The same study reported decreased p53 protein expression, interpreted as apoptosis inhibition, and the fibroblast lamin and cytoskeletal data are offered as the molecular correlate of an anti-apoptotic program.2 This is small, single-lab, Russian-language organ-culture work — hypothesis-generating, not efficacy evidence.

What doses appear in the literature?

Reported strictly as information, not a protocol. The actual scientific record is in-vitro: organotypic cultures used 10^-12 molar (picomolar) concentrations in the medium, with roughly 30-minute incubations in the fibroblast studies — bench concentrations, not body doses.12 Gray-market vendor and aggregator pages report subcutaneous injection of roughly 1 to 5 milligrams per day in cyclic courses of about 10 to 20 days, sometimes intranasally, mirroring generic Khavinson-peptide dosing folklore.67 There is no dose-finding, pharmacokinetic or safety study supporting any of these numbers, and no route has demonstrated bioavailability or efficacy in vivo. The mismatch between picomolar in-vitro activity and milligram injected 'doses' is itself a red flag that the gray-market regimens are not derived from the science.

How safe is Cardiogen?

Human safety data are nonexistent — there are no controlled toxicology or adverse-event datasets for Cardiogen in humans, so the absence of reported harm reflects absence of study, not demonstrated safety.1 The dominant concern is mechanistic and theoretical: the very actions marketed as beneficial — stimulating proliferation and suppressing p53 — are, in principle, the direction that could favor unchecked cell growth, and because p53 is a central tumor-suppressor, chronic downregulation is a non-trivial worry that is wholly untested in humans.1 Beyond the molecule itself, research-chemical peptides are not pharmaceutical-grade: sterility, endotoxin, identity and purity are unverified, carrying infection and immunogenicity risk. Injection-site reactions are generic to injected peptides, and drug interactions are entirely unstudied. Default-precaution populations include pregnancy and lactation, active or prior malignancy, pediatric use, and immunocompromised patients.

What is the FDA and WADA status in 2026?

Cardiogen is not an FDA-approved drug and is not among the peptides recognized for pharmacy compounding; it appears on no FDA Orange or Purple Book listing and is not a 503A or 503B compounding bulk substance.8 In the United States it is sold only as a 'research chemical — not for human use.' The FDA's stance, reinforced by its 2025 research-grade-peptide guidance enforceable from January 2026, presumes that peptides shipped to individuals with dosing instructions are intended for human use and treats that as an enforcement basis.9 It is not a DEA-controlled substance. The net status is a legally gray, unapproved research compound.

For athletes the picture is one of risk rather than a named ban. AEDR is not individually named on the WADA Prohibited List, but WADA's framework can capture substances with no current regulatory approval for human therapeutic use under the S0 'non-approved substances' catch-all, and anti-doping bodies advise treating research-only peptides as prohibited-risk.10 Any athlete in tested sport should regard Cardiogen as high-risk and assume it could trigger a sanction.

Bottom line. Cardiogen (AEDR) is scientifically interesting but clinically unproven. The honest picture is a coherent in-vitro mechanism — nuclear and histone binding, increased cardiomyocyte and fibroblast proliferation, reduced p53, raised lamins and cytoskeleton — demonstrated almost entirely by a single Russian research network in cell and organ cultures, never in humans.123 From a root-cause perspective, cardiovascular aging is far better addressed by validated levers — metabolic health, blood pressure, lipids, exercise and sleep — than by an unapproved peptide with zero human evidence and a genuine theoretical concern around chronically suppressing p53. Treat Cardiogen as a laboratory research tool, not a therapy. Regulatory facts here are current as of June 2026 and should be re-verified thereafter.